Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
Congenital Heart Disease is a general term for a range of birth defects that affect the normal workings of the heart. The term congenital means the condition is present at birth. Congenital heart disease is one of the most common types of birth defect, affecting up to 9 in every 1,000 babies born in the UK. In most cases, no obvious cause of congenital heart disease is identified. However, there are some things known to increase the risk of the condition, including: Down’s syndrome, Rubella, Diabetes type2.
OMICS International organises 1000+ Global Events every Year in Conference series, on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 700+ open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members.
Scope & Importance
The symptoms for congenital heart disease are rapid heartbeat, rapid breathing, excessive sweating, extreme tiredness, a blue tingle to the skin(cyanosis), tiredness and rapid breathing when a baby is feeding, etc… there are many types of congenital heart disease. Some of them are Septal defects, Coarctation of the aorta, pulmonary valve stenosis, transposition of the great arteries, etc… The treatment for congenital heart disease usually depends on the defect you or your child has.Mild defects, such as holes in the heart, often don't need to be treated, as they may improve on their own and may not cause any further problems.If the defect is significant and is causing problems, surgery is usually required. Modern Surgical techniques can often restore most or all of the heart's normal function, and nowadays about 80% of children with congenital heart disease will survive into adulthood. However, people with congenital heart disease often do need treatment over their life and therefore require specialist review during childhood and adulthood. This is because people with complex heart problems can develop further problems with their heart rhythm or valves over time.
Sometimes CHD improves without treatment. Other defects are so small that they do not require any treatment. Most of the time CHD is serious and requires Surgical and/or medications. Medications include diuretics, which aid the body in eliminating water, salts, and digoxin for strengthening the contraction of the heart. This slows the heartbeat and removes some fluid from tissues. Some defects require surgical procedures to restore circulation back to normal and in some cases, multiple surgeries are needed. Interventional Cardiology now offers patients minimally invasive alternatives to surgery for some patients.
The Melody Transcatheter Pulmonary Valve (TPV), approved in Europe in 2006 and in the U.S. in 2010 under a Humanitarian Device Exemption (HDE), is designed to treat congenital heart disease patients with a dysfunctional conduit in their right ventricular outflow tract (RVOT). The RVOT is the connection between the heart and Lung; once blood reaches the lungs, it is enriched with oxygen before being pumped to the rest of the body. Transcatheter pulmonary valve technology provides a less-invasive means to extend the life of a failed RVOT conduit and is designed to allow physicians to deliver a replacement pulmonary valve via a catheter through the patient’s blood vessels.Most patients require lifelong specialized cardiac care, first with a pediatric cardiologist and later with an adult congenital cardiologist. There are more than 1.8 million adults living with congenital heart defects.
Congenital heart defects are serious and common conditions that have significant impact on morbidity, mortality, and healthcare costs in children and adults. · The most commonly reported incidence of congenital heart defects in the United States is between 4 and 10 per 1,000, clustering around 8 per 1,000 live births. · Continental variations in birth prevalence have been reported, from 6.9 per 1000 births in Europe to 9.3 per 1000 in Asia. · An estimated minimum of 32,000 infants are expected to be affected each year in the United States. Of these, an approximate 25%, or 2.4 per 1,000 live births, require invasive treatment in the first year of life. The most common types of defects in children are (at a minimum) ventricular septal defects, 620,000 people; ASD, 235,000 people; valvular pulmonary stenosis, 185,000 people; and patent ductus arteriosus, 173,000 people. The most common lesions seen in adults are ASD and TOF.
This page will be updated regularly.
This page was last updated on 14th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising